REGENXBIO ($RGNX): Sarepta Settles Patent Litigation With a $39 Million Payment

01 Bull / Base / Bear Scenario Table

These are descriptions of possible paths, not forecasts, and none of them is a recommendation. Each depends on evidence that is not yet public: the content of the full clinical hold letter, the additional imaging under review by REGENXBIO and NS Pharma, and the outcome of two readouts that have not occurred.

02 What would require reassessment?

The thesis combines an internally controlled Duchenne programme, partnered retinal development and licensed technology, while RGX-121 remains on hold. The existing hold and milestone-driven revenue are starting conditions, not new surprises. The following developments would change the assessment.

• Additional safety restrictions or new evidence. A broader safety signal, new trial requirements or restrictions affecting another programme could increase cost and delay. Continued observation alone does not establish that the MRI findings are benign or treatment-related; either conclusion requires evidence.
• Weak pivotal retina results or reduced partner commitment. ATMOSPHERE and ASCENT must establish their own efficacy and safety. The paid AbbVie milestone confirms an achieved development condition, not future success or payment of another milestone.
• Duchenne filing or evidence setbacks. The Q3 submission-initiation guidance has expired. Confirmation of submission, FDA acceptance and the eventual decision are different events. Additional evidence requirements or delays would change the development timetable without automatically ending the programme.
• Cash use exceeds the funded plan. The August guidance into Q4 2027 is conditional. Later operating cash use, royalty obligations and development commitments need comparison with actual cash and receipts. Neither one profitable quarter nor an unpaid contractual settlement amount establishes recurring funding.

These are conditional tests, not forecasts or recommendations. They require a new primary disclosure and reassessment of the relevant part of the thesis, rather than invalidating every historical fact.

03 Clinical Hold on RGX-121: What Changed on August 24, 2026

REGENXBIO announced on the morning of August 24, 2026 that the FDA had placed a clinical hold on RGX-121, the one-time gene therapy for Mucopolysaccharidosis type II also known as clemidsogene lanparvovec and presented through 2026 under the NAVSUNLI name. The hold followed the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study. In the same release the company said it does not expect to resubmit the RGX-121 Biologics License Application in the near term.

The findings are described as either a small nodule or a small cystic mass, identified in spine MRIs of five participants who received intracisternal or intraventricular RGX-121 approximately three to six years ago. Investigators deemed them nonserious, radiologists believe they are likely benign, and the company states there is no clinical or pathological evidence confirming their nature or causation. No brain nodules or masses were identified on any brain MRI. All five participants continue to do well clinically and have shown overall stability to improvement on neurocognitive and neurobehavioral assessments. Investigators plan to continue observation with periodic imaging only.

The findings came from the company itself. REGENXBIO implemented an expanded MRI monitoring plan covering both brain and spine a few months ago, after the clinical hold related to RGX-111. Because spine MRI is not normally performed for MPS in clinical practice or in trials, the company states that the underlying prevalence and clinical significance of such asymptomatic findings in this population is unknown.

What this replaces. Until this release the file rested on two parallel third-quarter BLA paths: the RGX-121 resubmission after the positive July Type A meeting, and the RGX-202 Duchenne filing. One of the two is now removed from the near-term calendar without a stated timeline for its return. The company and its partner NS Pharma are evaluating additional patient imaging and longer-term follow-up data and will incorporate FDA feedback, including the full clinical hold letter once received, into next steps.

Asymptomatic spine MRI findings in five CAMPSIITE participants; investigators call them nonserious, radiologists likely benign, causation unconfirmed.

Stated as on track in the same release; different capsid and route of administration from the MPS programs.

ATMOSPHERE and ASCENT remain the decisive wet AMD efficacy readouts, restated as on track on August 24.

June 30 cash plus the AbbVie milestone and July offering proceeds; runway guidance into Q4 2027, issued August 6, 2026.

04 Capital bridge after the July financing

REGENXBIO now reports the June 30 balance and July inflows directly. The company describes the combined position as approximately $313 million of pro forma cash, cash equivalents and marketable securities.

Finalized Q2 balance, compared with $240.9 million at December 31, 2025.

Received in July after first-patient dosing in the NAAVIGATE diabetic-retinopathy study.

Estimated net proceeds received in July after full exercise of the underwriters’ option.

05 Company Overview: What REGENXBIO Does

REGENXBIO is a biotechnology company built around adeno-associated virus, or AAV, gene therapy. The company’s central proposition is that certain genetic, neuromuscular, neurodegenerative and retinal diseases can be addressed by delivering genetic material that enables cells to produce a missing, deficient or therapeutically useful protein. This is conceptually different from chronic dosing with small molecules or standard biologics. In successful cases, gene therapy aims to create durable biological effect after a one-time administration.

Historical plan before August 24. The current stock narrative is concentrated in three programs. NAVSUNLI / RGX-121 is the rare-disease CNS gene-therapy program for MPS II / Hunter syndrome. RGX-202 is the Duchenne muscular dystrophy program that has completed confirmatory dosing and had guided BLA initiation for the now-ended Q3 2026. Surabgene lomparvovec, also known as sura-vec or ABBV-RGX-314, is the AbbVie-partnered retinal disease program in wet AMD and diabetic retinopathy. Together, these programs create a pipeline profile that spans ultra-rare pediatric neurodegeneration, a larger neuromuscular disease opportunity and chronic retinal disease. This earlier RGX-121 resubmission plan was superseded by the clinical hold; there is no current near-term resubmission timeline.

06 NAVSUNLI / RGX-121: The Core Rare-Disease Story

NAVSUNLI, formerly referred to as RGX-121 and now identified as clemidsogene lanparvovec-sngl, is designed as a potential one-time gene therapy for Mucopolysaccharidosis II, also known as MPS II or Hunter syndrome. Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase, often abbreviated as I2S. When the enzyme is deficient, glycosaminoglycans accumulate in tissues, contributing to progressive multi-system disease. In neuronopathic forms, central nervous system involvement can lead to developmental delay, neurological deterioration and severe life-limiting outcomes.

The therapeutic idea behind NAVSUNLI is to deliver the IDS gene to the central nervous system so cells can produce iduronate-2-sulfatase. Delivery within the CNS could create a durable source of I2S protein beyond the blood-brain barrier, potentially allowing cross-correction of cells throughout the CNS. This is important because conventional enzyme replacement therapy has limitations in addressing neurological disease when the therapeutic enzyme does not adequately cross the blood-brain barrier.

REGENXBIO has described NAVSUNLI as an investigational one-time gene therapy for boys with MPS II, designed to deliver the IDS gene to the CNS. The company has also stated that the expressed protein is structurally identical to normal I2S. NAVSUNLI has received Orphan Drug Product, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy designations from the FDA, and advanced therapy medicinal product classification from the European Medicines Agency. Those designations do not guarantee approval, but they confirm that regulators have recognized the seriousness and rarity of the condition and the potential relevance of the program.

The regulatory design of the program has always been central. REGENXBIO sought accelerated approval, a pathway that can allow approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory evidence required later. For NAVSUNLI, the key biomarker discussion has centered on CSF HS D2S6, a measure linked by the company to brain disease activity in MPS II. The scientific and regulatory question is whether changes in that biomarker, combined with clinical, functional and longer-term evidence, are sufficient to support a conclusion that the therapy is reasonably likely to provide clinical benefit.

The CAMPSIITE NCT03566043 registry was last updated January 28, 2025 and still displays ACTIVE_NOT_RECRUITING. It predates the August 2026 hold and must not override the newer company 8-K. No public FDA hold-lift confirmation was found in the sources reviewed.

07 The Timeline: From FDA Acceptance to CRL to Reopened Path

08 The February 2026 CRL: What Went Wrong

The February CRL is essential to understand because the June 2026 NAVSUNLI update only matters in relation to what the FDA previously objected to. The agency had accepted the BLA under accelerated approval in May 2025, but the February CRL indicated that the FDA was not prepared to approve the gene therapy at that time. The concerns were not superficial. They involved patient selection, evidence comparability and the surrogate endpoint foundation of the accelerated-approval request.

The first issue was patient-population definition. In MPS II, the difference between neuronopathic and attenuated disease is critical. A therapy aimed at altering neurological disease progression must show that the treated population is appropriately defined as having the disease form that the therapy is intended to address. If the FDA is uncertain that the eligibility criteria adequately distinguish neuronopathic disease from attenuated disease, the agency may also question how to interpret biomarker and functional outcomes.

The second issue was the external natural-history control. In ultra-rare diseases, companies often rely on natural-history comparisons because randomized placebo-controlled trials may be impractical, slow or ethically difficult. But external controls create their own problems. Treated patients and historical comparison groups must be sufficiently comparable. Differences in baseline disease severity, age, genotype, clinical trajectory, measurement frequency, supportive care or data quality can distort interpretation of treatment effect. If the FDA does not believe the external control is comparable enough, the strength of the evidence package is weakened.

The third issue was the surrogate endpoint. Accelerated approval depends on whether a surrogate endpoint is reasonably likely to predict clinical benefit. For NAVSUNLI, the relevant biomarker discussion involves CSF HS D2S6. REGENXBIO’s argument is that this biomarker is tied to brain disease activity in MPS II. The FDA’s February CRL raised concern about the appropriateness of that surrogate endpoint as a basis for approval. This is the core of the accelerated-approval case.

The CRL listed several potential paths forward, including a new study, treating additional patients, longer-term follow-up and use of an untreated control arm. For a large disease population, those options might be burdensome but feasible. For ultra-rare MPS II, they are far more challenging. REGENXBIO’s February language made clear that the company viewed the suggested paths as difficult in the context of an irreversible, progressive, ultra-rare disease.

The June/July agreement, as described by REGENXBIO, did not call for new studies for the then-planned resubmission. That pre-hold position does not establish what additional evidence FDA may require to resolve the August 24 safety hold. The original evidence questions and the new safety question must both be addressed.

09 RGX-202: Duchenne evidence and the expired Q3 filing window

RGX-202 is REGENXBIO’s investigational gene therapy for Duchenne muscular dystrophy, a rare, progressive neuromuscular disease characterized by muscle weakness and loss of function. Duchenne is a larger commercial opportunity than MPS II, but it is also a highly competitive and scientifically demanding field. The history of Duchenne drug development has included intense debate around surrogate endpoints, functional outcomes, durability, safety and regulatory flexibility.

On May 14, 2026, REGENXBIO announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE study. The company said the trial achieved its primary endpoint with high statistical significance, with 93% of patients achieving RGX-202 microdystrophin expression above 10% at Week 12. It also reported a statistically significant correlation between RGX-202 microdystrophin expression and functional improvement on NSAA in the interim functional dataset, supporting the validity of the surrogate endpoint in the company’s interpretation.

The pivotal dataset included 30 evaluable participants with Week 12 biopsy data, 31 participants in the interim safety dataset and nine participants with 12-month functional data at the time of the topline update. REGENXBIO described RGX-202 as well tolerated. Its May 14 report also disclosed two serious adverse events: subacute myocarditis in an eight-year-old and asymptomatic liver injury in a ten-year-old. Both resolved within weeks without sequelae, according to the company. These RGX-202 findings are separate from the RGX-121/111 clinical holds. May 14 primary safety disclosure. The company highlighted the differentiated design of RGX-202, including a novel microdystrophin construct that includes the C-Terminal domain, a proactive immune suppression regimen and suspension-based manufacturing.

The June 24 update pushed the program further forward. REGENXBIO announced successful completion of dosing in the confirmatory study of RGX-202, describing the milestone as completion of the registrational development program. The June 24 release guided BLA initiation in Q3 2026 under the accelerated approval pathway; that window has expired and requires a new status confirmation. It says the BLA submission will include a substantial safety dataset from 63 participants across the pivotal and confirmatory AFFINITY DUCHENNE studies, efficacy data from 30 participants in the pivotal portion and 12-month functional data for at least half of the total participants in the pivotal study.

The main risk is that Duchenne remains a difficult regulatory arena. The FDA may agree that the package supports review, or it may require additional evidence. Functional data maturity, durability, immune response, serious adverse events, manufacturing comparability and commercial readiness will all matter. Traders should also remember that “potential approval in 2H 2027” is a company framing, not an FDA guarantee.

AFFINITY DUCHENNE NCT05693142 is ACTIVE_NOT_RECRUITING in the July 21 registry, with 65 estimated participants across the entire study and estimated September 2026 primary completion. Those fields are distinct from the company’s 30-patient pivotal biomarker set and 63-participant planned BLA safety package. Neither the registry date nor dosing completion confirms BLA submission or FDA acceptance.

10 Sura-vec / ABBV-RGX-314: Retina Optionality and the AbbVie $100M Milestone

Surabgene lomparvovec, or sura-vec / ABBV-RGX-314, is REGENXBIO’s investigational retinal gene therapy being developed in collaboration with AbbVie for wet age-related macular degeneration, diabetic retinopathy and potentially other chronic retinal conditions. The program uses the NAV AAV8 vector to encode an antibody fragment designed to inhibit vascular endothelial growth factor, or VEGF. The therapeutic goal is to deliver a sustained treatment effect after one-time administration rather than relying on repeated anti-VEGF injections.

The June 29, 2026 NAAVIGATE announcement is important because it triggers a concrete partner payment. REGENXBIO announced that the first patient had been dosed in the Phase IIb/III NAAVIGATE clinical trial in diabetic retinopathy using suprachoroidal delivery. Under the AbbVie collaboration, that milestone results in a $100 million payment to REGENXBIO. The study is evaluating sura-vec in subjects with non-proliferative diabetic retinopathy without center-involved diabetic macular edema. Participants receive sura-vec at 1.0×10^12 genome copies per eye, the dose previously evaluated as dose level 3 in the Phase II ALTITUDE trial, and short-course topical prophylactic steroids.

The primary endpoint of NAAVIGATE is greater than two-step improvement on the diabetic retinopathy severity scale at one year. The Phase IIb portion, operationalized by REGENXBIO, is expected to enroll approximately 135 participants in the United States. This means the diabetic retinopathy program is entering a more meaningful test of whether a one-time, in-office gene therapy can prevent disease progression and reduce the burden of repeated interventions.

The retina program also has important forward data visibility. At ASRS 2026, REGENXBIO presented two-and-a-half-year data from the ALTITUDE long-term follow-up study in diabetic retinopathy and five-year follow-up data from the Phase I/IIa subretinal wet AMD study. Separately, the company expects to announce topline data with AbbVie from the ATMOSPHERE and ASCENT pivotal trials of sura-vec using subretinal delivery in wet AMD in Q4 2026. On September 24, 2026, the Retina Society update extended ALTITUDE follow-up to three years (data cut-off August 17). At Dose Level 3, 6/10 participants with a year-three visit had >2-step DRSS improvement without additional diabetic retinopathy treatment. No new sura-vec-related safety signals or intraocular inflammation were reported through three years in 17 participants receiving short-course topical steroid prophylaxis. These are interim results from a small follow-up sample, not a pivotal comparison or a wet AMD outcome.

Registry cross-check: ATMOSPHERE NCT04704921 lists 671 actual participants and estimated primary completion December 2026 (April 28 update); ASCENT NCT05407636 lists 735 actual participants and estimated primary completion October 2026 (August 3 update). Both are ACTIVE_NOT_RECRUITING. These are registry estimates, while the company still guides joint topline disclosure in Q4 2026; no exact readout day is verified.

11 Financial Snapshot: Final Q2 Results, $313M Pro Forma Liquidity and Q4 2027 Runway

REGENXBIO reported $108.0 million of revenue for Q2 2026, compared with $21.4 million in Q2 2025. License and royalty revenue was $103.8 million and service revenue was $4.2 million. The year-over-year increase was driven primarily by the $100 million AbbVie development milestone earned when the first patient was dosed in NAAVIGATE. That milestone is economically important but non-recurring, so the headline revenue growth should not be extrapolated as a new quarterly run rate.

R&D expense was $56.1 million, down from $59.5 million a year earlier, primarily because of lower manufacturing-related and clinical-trial expenses for sura-vec and NAVSUNLI pivotal studies. G&A expense rose to $21.6 million from $19.9 million, reflecting personnel, commercialization preparation, consulting and corporate advisory costs. Total operating expenses were $78.8 million.

GAAP net income was $22.7 million, or $0.43 per basic and diluted share, compared with a $70.9 million loss, or $1.38 per share, in the prior-year quarter. The EPS quality screen is essential: the quarter moved into profit because the one-time milestone lifted operating income to $29.3 million. Excluding that $100 million milestone as a simple analytical sensitivity—not a company-reported non-GAAP measure—the quarter would still reflect a substantial operating loss. The reported profit therefore should not be interpreted as recurring commercial profitability.

Cash, cash equivalents and marketable securities were $105.5 million at June 30, 2026, down from $240.9 million at December 31, 2025 as the company funded operations. In July, REGENXBIO received the $100 million AbbVie milestone and approximately $107.8 million of estimated net proceeds from the underwritten offering after the underwriters exercised their option in full. The company reported approximately $313 million of pro forma liquidity and now expects the current operating plan to be funded into Q4 2027.

Dilution: the final structure is known, but the improved runway is now official

The July offering issued 11,671,139 common shares including the fully exercised 1,667,250-share option, and 1,111,111 pre-funded warrants: 12,782,250 new equivalents. The latest common count is 66,013,192 at July 31. Legacy June pre-funded warrants (869,603), new July warrants and other equity awards must be reconciled separately; the previous 19.2% dilution estimate used an older base and is not the current share count.

What existing holders paid: the company accepted material dilution at $9.00 per common share and $8.9999 per pre-funded warrant. The full option exercise realized the upper end of the previously modeled dilution range.

What the transaction bought: the financing and AbbVie milestone convert a near-term liquidity concern into company-guided runway into Q4 2027. That does not remove future financing risk, but it gives REGENXBIO more time to execute the RGX-202 filing and the unresolved RGX-121 safety response, obtain Q4 retina data and prepare for potential commercialization.

The June 10-Q records H1 operating cash use of $138.424M and a $67.342M net loss, despite the milestone-driven Q2 profit. The milestone was earned into Q2 revenue and receivables, then collected in July: adding the July receipt to June cash is correct, but it is not new Q3 revenue a second time. Reported royalty-monetization liabilities total $181.511M at June 30, including a $169.704M 2025 royalty-bond carrying value and $11.807M under the 2020 arrangement. These are financing obligations backed by specified royalty streams, not a reason to call the company debt-free. The 2025 facility maximum is $250M; only its initial $150M gross tranche was funded in May 2025, already in historical cash flows. Later conditional tranches must not be counted as received.

The June-quarter ATM sold 2,318,735 shares for $18.9M net under a $150M program. These shares and proceeds are already incorporated in June accounts; do not add them again to July common shares or liquidity. Pre-funded exercises bring only nominal incremental cash.

SEC · cash flows and notes 7–9

The recurring royalty comparison also changed. The August release attributes a $16.7 million year-over-year decline in Q2 ZOLGENSMA royalty revenue to expiry of licensed U.S. patents in January 2026. It separately identifies royalties on certain ITVISMA sales under patents extending to 2037. The milestone therefore masks a change in the underlying royalty mix; licensed sales, applicable territories and patent terms must be assessed separately. Q2 release.

12 Partnerships and Commercial Structure

REGENXBIO’s pipeline includes both partnered and internally controlled economics, and this matters for valuation. NAVSUNLI and RGX-111 are partnered with Nippon Shinyaku, including NS Pharma in the United States. Under the strategic partnership announced in January 2025, following potential FDA approval, RGX-121 / NAVSUNLI would be commercialized by NS Pharma in the United States. REGENXBIO retains manufacturing and other roles, and the arrangement affects how investors should think about launch execution, costs, revenue recognition and potential milestone economics.

Sura-vec / ABBV-RGX-314 is partnered with AbbVie, which brings the retina program into a different category. AbbVie’s role is important because retinal disease development can be expensive, global and commercially competitive. The amended diabetic retinopathy milestone structure included $100 million upon first subject dosed in the Phase IIb/III trial and an additional $100 million upon first subject dosed in a second Phase III trial. The first of those milestones has now been triggered. The second remains a future event and should not be counted as received.

RGX-202 is particularly important because it is a major internal late-stage program. If approved, it could become a central commercial asset for REGENXBIO. That is why manufacturing readiness matters. The company has highlighted its end-to-end, commercial-ready in-house manufacturing at the REGENXBIO Manufacturing Innovation Center in Rockville, Maryland, and has stated that production intended for commercial supply was initiated last year. In gene therapy, commercial manufacturing is not an afterthought. Product consistency, release testing, vector quality, full/empty capsid controls, batch reliability and supply readiness can all influence regulatory and commercial execution.

13 Management, board changes and execution

Curran Simpson remains President and CEO. The immediate operational priorities are the RGX-121 safety response, RGX-202 filing preparation, AbbVie-partnered pivotal data and cash management. July regulatory alignment on RGX-121 is historical context; a renewed resubmission schedule requires evidence that the clinical hold has been addressed.

The August 25 8-K records Gregory Ciongoli’s independent-director appointment and the resignations of Jean Bennett and Jerry Karabelas, who remain advisers until February 2027 unless extended. The board shrank to nine. Ciongoli joined Audit and Nominating/Corporate Governance and received an initial $550,000 grant-date-value award, split 75% options and 25% RSUs. Governance changes and subsequent purchases are disclosed events, not evidence that FDA will lift the hold.

SEC · board

14 Ownership, insider transactions and current market data

Ciongoli’s August 27 Form 4 reports open-market purchases, code P: 49,196 shares on August 26 at weighted $9.1411 and 53,407 on August 27 at $9.356, 102,603 in total. These are distinct from the August 25 award of 15,432 RSUs and 69,609 options at $8.91. The September 3 Forms 4 for Malzahn and Chan instead show code F tax withholding on September 1, 234 and 4,902 shares at $9.32. They are not open-market sales. Buying increases the director’s exposure but does not establish nonpublic regulatory knowledge or approval probability.

SEC · Ciongoli Form 4 · SEC · Malzahn · SEC · Chan

15 Retail sentiment: limits of the available evidence

Retail discussion reflects opinion and attention; it does not establish a clinical result, regulatory approval or commercial demand.

This is attention and positioning context, not independent clinical evidence or an investment signal. The safety disclosure and next official filing remain the relevant factual tests.

16 Key Catalysts and Execution Checks